{"title":"日本青少年特发性关节炎患者未满足医疗需求的验证。","authors":"Masaki Shimizu, Eisuke Inoue, Ryoko Sakai, Yuzaburo Inoue, Kanako Mitsunaga, Takahiko Sugihara, Toru Hirano, Kazushi Izawa, Dai Kishida, Masakazu Matsushita, Masaaki Mori, Hidehiko Narazaki, Ryuta Nishikomori, Shuji Sumitomo, Takayuki Tanaka, Susumu Yamazaki, Ken Yamaji, Naoto Yokogawa, Hajime Yoshifuji, Takako Miyamae","doi":"10.1093/mr/roaf032","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To identify unmet medical needs (UMNs) of medical practices and investigate the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with juvenile idiopathic arthritis (JIA).</p><p><strong>Methods: </strong>Possible UMNs were collected from eight pediatric and eight adult rheumatologists. To verify UMNs, the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with JIA were described using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB).</p><p><strong>Results: </strong>Fifty-eight possible UMNs collected from 16 experts and 35 UMNs were investigated using NDB. The highest priority UMNs was the expansion of indications for subcutaneous tocilizumab (TCZ sc) and subcutaneous abatacept (ABT sc)-TCZ sc was administered to 12.8% systemic JIA and 5.5% JIA with polyarthritis or oligoarthritis. Comorbidities for systemic JIA and JIA with polyarthritis or oligoarthritis included hypertension (7.1%, 1.3%), osteoporosis (17%, 5.4%), depression (2.3%, 1.3%), diabetes (1.9% systemic JIA), and iritis and/or uveitis (6.5% JIA with polyarthritis or oligoarthritis).</p><p><strong>Conclusions: </strong>The highest priority UMNs for JIA was the expansion of indications for ABT sc and especially TCZ sc. This study reveals the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with JIA in Japan.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan.\",\"authors\":\"Masaki Shimizu, Eisuke Inoue, Ryoko Sakai, Yuzaburo Inoue, Kanako Mitsunaga, Takahiko Sugihara, Toru Hirano, Kazushi Izawa, Dai Kishida, Masakazu Matsushita, Masaaki Mori, Hidehiko Narazaki, Ryuta Nishikomori, Shuji Sumitomo, Takayuki Tanaka, Susumu Yamazaki, Ken Yamaji, Naoto Yokogawa, Hajime Yoshifuji, Takako Miyamae\",\"doi\":\"10.1093/mr/roaf032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To identify unmet medical needs (UMNs) of medical practices and investigate the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with juvenile idiopathic arthritis (JIA).</p><p><strong>Methods: </strong>Possible UMNs were collected from eight pediatric and eight adult rheumatologists. To verify UMNs, the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with JIA were described using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB).</p><p><strong>Results: </strong>Fifty-eight possible UMNs collected from 16 experts and 35 UMNs were investigated using NDB. The highest priority UMNs was the expansion of indications for subcutaneous tocilizumab (TCZ sc) and subcutaneous abatacept (ABT sc)-TCZ sc was administered to 12.8% systemic JIA and 5.5% JIA with polyarthritis or oligoarthritis. Comorbidities for systemic JIA and JIA with polyarthritis or oligoarthritis included hypertension (7.1%, 1.3%), osteoporosis (17%, 5.4%), depression (2.3%, 1.3%), diabetes (1.9% systemic JIA), and iritis and/or uveitis (6.5% JIA with polyarthritis or oligoarthritis).</p><p><strong>Conclusions: </strong>The highest priority UMNs for JIA was the expansion of indications for ABT sc and especially TCZ sc. This study reveals the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with JIA in Japan.</p>\",\"PeriodicalId\":18705,\"journal\":{\"name\":\"Modern Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mr/roaf032\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roaf032","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan.
Objectives: To identify unmet medical needs (UMNs) of medical practices and investigate the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with juvenile idiopathic arthritis (JIA).
Methods: Possible UMNs were collected from eight pediatric and eight adult rheumatologists. To verify UMNs, the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with JIA were described using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB).
Results: Fifty-eight possible UMNs collected from 16 experts and 35 UMNs were investigated using NDB. The highest priority UMNs was the expansion of indications for subcutaneous tocilizumab (TCZ sc) and subcutaneous abatacept (ABT sc)-TCZ sc was administered to 12.8% systemic JIA and 5.5% JIA with polyarthritis or oligoarthritis. Comorbidities for systemic JIA and JIA with polyarthritis or oligoarthritis included hypertension (7.1%, 1.3%), osteoporosis (17%, 5.4%), depression (2.3%, 1.3%), diabetes (1.9% systemic JIA), and iritis and/or uveitis (6.5% JIA with polyarthritis or oligoarthritis).
Conclusions: The highest priority UMNs for JIA was the expansion of indications for ABT sc and especially TCZ sc. This study reveals the real-world prescribing practices of therapeutic medical treatments and test implementation for patients with JIA in Japan.
期刊介绍：
Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery.
Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered.
Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
